申请人:Lonza Ltd.
公开号:US05352801A1
公开(公告)日:1994-10-04
Starting from 5-alkylidene or 5-benzylidenetetramic acid optically-active 4-amino-3-hydroxy-carboxylic acids are produced in the (rel-3R,4R) configuration, especially statine. The synthesis process includes the O-acylation of the tetramic acid to the corresponding 4-acyloxy-3-pyrrolin-2-one, a stereoselective hydrogenation to (rel-4R,5R)-4-acyloxy-5-alkyl or 5-benzylpyrrolidin-2-one and an enantioselective enzymatic hydrolysis of the (4R,5R)-enantiomer to the corresponding 4-hydroxypyrrolidin-2-one. The nonhydrolyzed enantiomer is separated and converted into the target compound with (3S,4S) configuration by hydrolytic cleavage of the lactam ring and the ester function and optionally introduction of an amino protective group. Analogously the (3R,4R)-enantiomer can be obtained from the 4-hydroxypyrrolidin-2-one from the enzymatic hydrolysis. The 4-amino-3-hydroxycarboxylic acids producible according to the invention are the structural elements of enzyme inhibitors.
从5-烷基亚甲基或5-苯甲基亚甲基四元酸开始,通过合成过程制备出(rel-3R,4R)构型的光学活性4-氨基-3-羟基-羧酸,尤其是statine。合成过程包括将四元酸进行O-酰化,制备相应的4-酰氧基-3-吡咯烷酮,进行立体选择性氢化制备出(rel-4R,5R)-4-酰氧基-5-烷基或5-苯甲基吡咯烷酮,并进行对映选择性的酶催化水解,制备相应的4-羟基吡咯烷酮。未水解的对映体被分离并通过内酰胺环和酯基的水解以及可能的氨基保护基的引入转化为具有(3S,4S)构型的目标化合物。类似地,(3R,4R)对映体可以从酶催化水解得到的4-羟基吡咯烷酮中获得。根据本发明可制备的4-氨基-3-羟基羧酸是酶抑制剂的结构元素。